Karyopharm Therapeutics Inc.
KPTI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001503802
In the last 90 days, Karyopharm Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 96 institutions reported holding it in 13F filings for Q2 2026, worth $206.8M in total; no superinvestor holds it.
Key figures
- Market capCalculated value looks implausible
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.14K in total
- 3
- 13F holdersQ2 2026, +19 vs. previous quarter
- 96
- 13F valueReported value at the end of Q2 2026
- $206.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $146.1M
- +0.6% year over year
- Net income, FY2025
- -$196.0M
- No comparable prior period
- Free cash flow, FY2025
- -$75.4M
- No comparable prior period
- Revenue, Q2 FY2026
- $33.4M
- −11.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $196.0M (134.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.23M
- Shares sold short
- Change
- +965.2K
- +13.3% vs. previous
- Days to cover
- 1.09
- At average daily volume
Superinvestors holding KPTI, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KPTI at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Karyopharm Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 (view filing)4:03 PM ET | Oct 16 | 3 days | Abate KristinChief Accounting Officer | SSale | −4.79K | $0.344 | −$1.65K | −20.5%18.6K after | |
| Oct 2, 2026 (view filing)4:01 PM ET | Oct 1 | 1 day | Abate KristinChief Accounting Officer | SSale | −378 | $1.19 | −$449.82 | −1.6%23.4K after | |
| Sep 2, 2026 (view filing)4:57 PM ET | Sep 1 | 1 day | Abate KristinChief Accounting Officer | SSale | −19 | $2.02 | −$38.38 | −0.1%23.8K after | |
| Jul 30, 2026 (view filing)4:42 PM ET | Jul 28 | 2 days | Poulton StuartEVP, Chief Development Officer | SSale | −189 | $7.10 | −$1.34K | −0.2%94.6K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Poulton StuartEVP, Chief Development Officer | SSale | −403 | $9.50 | −$3.83K | −0.4%94.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Rangwala ReshmaEVP & Chief Medical Officer | SSale | −408 | $9.50 | −$3.88K | −0.7%56.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Cheng Sohanya RoshanEVP & Chief Commercial Officer | SSale | −324 | $9.50 | −$3.08K | −0.3%107.9K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Abate KristinChief Accounting Officer | SSale | −53 | $9.50 | −$503.5 | −0.2%23.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Paulson Richard A.President and CEO | SSale | −2.20K | $9.50 | −$20.9K | −0.8%269.7K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Mano MichaelEVP, CLO&Secretary | SSale | −266 | $9.50 | −$2.53K | −0.3%94.4K after |
Top 10 13F holders, Q2 2026
See all 96 holdersThe largest institutional positions in Karyopharm Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 1,917,354 | $18.7M | 0.16% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,521,322 | $14.9M | 0.02% | −285,000−15.8% | Reduced |
| Acorn Capital Advisors, LLC | 1,518,113 | $14.8M | 4.05% | +1,230,287+427.4% | Added |
| Goldman Sachs Group Inc | 1,424,658 | $13.9M | 0.00% | +477,079+50.3% | Added |
| BlackRock, Inc. | 1,418,799 | $13.9M | 0.00% | +1,173,900+479.3% | Added |
| Vanguard Capital Management LLC | 958,979 | $9.37M | 0.00% | +219,234+29.6% | Added |
| Catalio Capital Management, LP | 940,855 | $9.19M | 1.73% | +43,146+4.8% | Added |
| Avidity Partners Management LP | 924,487 | $9.03M | 1.45% | +460,746+99.4% | Added |
| T. Rowe Price Investment Management, Inc. | 786,309 | $7.68M | 0.01% | −755,781−49.0% | Reduced |
| Two Sigma Investments, LP | 695,264 | $6.79M | 0.01% | +544,032+359.7% | Added |
Holders of 5% or more of KPTI
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Karyopharm Therapeutics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13G/A | 9.90%2.30M shares | 0.00 ppfrom 9.90% | Apr 2, 20262 filings | Aug 14, 2026 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 8.60%2.07M shares | 0.00 ppfrom 8.60% | Apr 10, 20253 filings | May 14, 2026 | SEC |
| Adage Capital Management, L.P. | 13G/A | 6.78%1.54M shares | −1.30 ppfrom 8.08% | Feb 12, 20254 filings | Aug 12, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G/A | 6.60%1.54M shares | −5.20 ppfrom 11.80% | Aug 14, 20254 filings | Jun 5, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.60%1.27M shares | New | Jul 28, 20261 filing | Jul 28, 2026 | SEC |
Politician trades
All politician trades in KPTI1 member of Congress reported 1 trade in Karyopharm Therapeutics Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Mar 22, 2025 |  Ashley Moody Senate · FL | Sell (full) | $1K-$15K |
Senate · FL · Mar 22, 2025
Sell (full)$1K-$15K